22 results on '"Voskuyl, Alexandre"'
Search Results
2. Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases
- Author
-
Wieske, Luuk, Kummer, Laura Y. L., van Dam, Koos P. J., Stalman, Eileen W., van der Kooi, Anneke J., Raaphorst, Joost, Löwenberg, Mark, Takkenberg, R. Bart, Volkers, Adriaan G., D’Haens, Geert R. A. M., Tas, Sander W., Spuls, Phyllis I., Bekkenk, Marcel W., Musters, Annelie H., Post, Nicoline F., Bosma, Angela L., Hilhorst, Marc L., Vegting, Yosta, Bemelman, Frederike J., Killestein, Joep, van Kempen, Zoé L. E., Voskuyl, Alexandre E., Broens, Bo, Sanchez, Agner Parra, Wolbink, Gertjan, Boekel, Laura, Rutgers, Abraham, de Leeuw, Karina, Horváth, Barbara, Verschuuren, Jan J. G. M., Ruiter, Annabel M., van Ouwerkerk, Lotte, van der Woude, Diane, Allaart, Cornelia F., Teng, Y. K. Onno, van Paassen, Pieter, Busch, Matthias H., Jallah, B. Papay, Brusse, Esther, van Doorn, Pieter A., Baars, Adája E., Hijnen, Dirkjan, Schreurs, Corine R. G., van der Pol, W. Ludo, Goedee, H. Stephan, Steenhuis, Maurice, Rispens, Theo, ten Brinke, Anja, Verstegen, Niels J. M., Zwinderman, Koos A. H., van Ham, S. Marieke, Kuijpers, Taco W., and Eftimov, Filip
- Published
- 2022
- Full Text
- View/download PDF
3. A genome wide association study follow-up suggests a possible role of PPARG in systemic esclerosis susceptiblity
- Author
-
López Isac, Elena, Bossini Castillo, Lara, Simeón Aznar, Carmen Pilar, Egurbide Arberas, María Victoria, Alegre-Sancho, Juan José, Callejas Rubio, José Luis, Román-Ivorra, José Andrés, Freire, Mayka, Beretta, Lorenzo, Santaniello, Alessandro, Airó, Paolo, Lunardi, Claudio, Hunzelmann, Nicolas, Riemestaken, Gabriela, Witte, Torsten, Kreuter, Alexander, Distler, Jörg H.V., Schuerwegh, Annemie J., Vonk, Madelon C., Voskuyl, Alexandre E., Shiels, Paul G., van Laar, Jacob M., Fonseca, Carmen, Denton, Christopher P., Herrick, Ariane L., Worthington, Jane, Assassi, Shervin, Koeleman, Bobby P. C., Mayes, Maureen D., Radstake, Timothy R.D.J., Martín, Javier, Espinosa Garriga, Gerard, Spanish Scleroderma Study Group (SSSG), Narváez García, Francisco Javier, Universidad de Cantabria, Rheumatology, CCA - Disease profiling, Sociedad Española de Reumatología, Ministerio de Economía y Competitividad (España), Junta de Andalucía, European League Against Rheumatism, Ministerio de Educación, Cultura y Deporte (España), Netherlands Organization for Scientific Research, Dutch Arthritis Foundation, National Institutes of Health (US), National Institute of Arthritis and Musculoskeletal and Skin Diseases (US), Congressionally Directed Medical Research Programs (US), and Universitat de Barcelona
- Subjects
Adult ,Male ,Peroxisome proliferator-activated receptor gamma ,Genotype ,Autoimmune diseases ,Immunology ,Genome-wide association study ,Single-nucleotide polymorphism ,Bioinformatics ,Genoma humà ,Polymorphism, Single Nucleotide ,PPARG gene ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,GWAS ,Humans ,Immunology and Allergy ,Medicine ,Genetic Predisposition to Disease ,Genotyping ,030304 developmental biology ,030203 arthritis & rheumatology ,0303 health sciences ,Scleroderma, Systemic ,Malalties autoimmunitàries ,Human genome ,business.industry ,Middle Aged ,3. Good health ,SNP genotyping ,PPAR gamma ,Scleroderma (Disease) ,SYSTEMIC SCLEROSIS ,Cohort ,Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5] ,Female ,SNPs ,Esclerodèrmia ,business ,Genome-Wide Association Study ,Research Article ,Cohort study - Abstract
[Introduction] A recent genome-wide association study (GWAS) comprising a French cohort of systemic sclerosis (SSc) reported several non-HLA single-nucleotide polymorphisms (SNPs) showing a nominal association in the discovery phase. We aimed to identify previously overlooked susceptibility variants by using a follow-up strategy., [Methods] Sixty-six non-HLA SNPs showing a P value, [Results] We observed nominal associations for both PPARG rs310746 (P MH = 1.90 × 10-6, OR, 1.28) and CHRNA9 rs6832151 (P MH = 4.30 × 10-6, OR, 1.17) genetic variants with SSc in the first step of our study. In the replication phase, we observed a trend of association for PPARG rs310746 (P value = 0.066; OR, 1.17). The combined overall Mantel-Haenszel meta-analysis of all the cohorts included in the present study revealed that PPARG rs310746 remained associated with SSc with a nominal non-genome-wide significant P value (P MH = 5.00 × 10-7; OR, 1.25). No evidence of association was observed for CHRNA9 rs6832151 either in the replication phase or in the overall pooled analysis., [Conclusion] Our results suggest a role of PPARG gene in the development of SSc., This work was supported by the following grants: JM was funded by GEN-FER from the Spanish Society of Rheumatology, SAF2009-11110 and SAF2012-34435 from the Spanish Ministry of Economy and Competitiveness, CTS-4977, and CTS-180 from Junta de Andalucía, and is sponsored by the Orphan Disease Program grant from the European League Against Rheumatism (EULAR). This study was also funded by PI-0590-2010, from Consejería de Salud y Bienestar Social, Junta de Andalucía, Spain. JLCR and JM are funded by Consejería de Salud, Junta de Andalucía, through PI-0590-2010. ELI was supported by Ministerio de Educación, Cultura y Deporte through the program FPU. TRDJR was funded by the VIDI laureate from the Dutch Association of Research (NWO) and Dutch Arthritis Foundation (National Reumafonds). TW was granted by DFG WI 1031/6.1. Study on USA samples were supported by US National Institutes of Health and National Institute of Arthritis and Musculoskeletal Diseases (NIH-NIAMS) R01-AR-055258, Two-Stage Genome Wide Association Study in Systemic Sclerosis (MDM) and by the NIH-NIAMS Center of Research Translation (CORT) in SSc (P50AR054144) (MDM, FCA, FKT), the NIH-NIAMS SSc Family Registry and DNA Repository (N01-AR-0-2251) (MDM), NIH-KL2RR024149 (SA), K23AR061436 (SA), and the Department of Defense Congressionally Directed Medical Research Programs (W81XWH-07-01-0111) (MDM).
- Published
- 2014
4. Relation between duration of the prodromal phase and renal damage in ANCA-associated vasculitis.
- Author
-
Houben, Eline, Groenland, Stefanie L., van der Heijden, Joost W., Voskuyl, Alexandre E., Doodeman, Hiëronymus J., and Penne, Erik L.
- Subjects
VASCULITIS ,VASCULITIS treatment ,DISEASE progression ,GLOMERULAR filtration rate ,CATASTROPHIC illness ,DIAGNOSIS - Abstract
Background: In ANCA-associated vasculitis the acute phase of the disease is often preceded by prodromal symptoms. The aim of the present study was to analyze the relation between the duration of the prodromal phase and renal damage.Methods: Patients with ANCA-associated vasculitis and renal involvement from a retrospective single-center cohort were divided into two equal groups based on the duration of the prodromal phase. The prodromal phase was defined as the time between first vasculitis related symptoms and the date of diagnosis. Clinical characteristics at diagnosis and renal items on the vasculitis damage index at 6 months were compared between the two groups. In addition, the relation between a long prodromal phase and 3-year end-stage renal disease and mortality as a composite outcome was studied.Results: A total of 72 patients were included (age 64 ± 12 years; 74% male; 96% Caucasian). At diagnosis, in patients with a prodromal phase ≤22 weeks versus >22 weeks estimated glomerular filtration rate and proteinuria did not differ significantly (35 (interquartile range 50) versus 30 (50) ml/min p = 0.84; 75% versus 87%, p = 0.21 respectively). Furthermore, Birmingham Vasculitis Activity Scores were comparable (7 (3), p = 0.71). At 6 months, a long prodromal phase was associated with proteinuria (odds ratio 5.38, 95% confidence interval (CI) 1.47-19.62), but not with an estimated glomerular filtration rate ≤ 50 ml/min (odds ratio 0.89, 95% CI 0.33-2.37) in multivariable analyses. In addition, a long prodromal phase was associated with end-stage renal disease/mortality (hazard ratio 5.22, 95% CI 1.13-24.20).Conclusions: A long prodromal phase was associated with proteinuria and 3-year end-stage renal disease/mortality, but not with a reduced renal function at 6 months. These results underline the importance of an early diagnosis in ANCA-associated vasculitis patients in order to improve renal outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
5. B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients.
- Author
-
Bruijnen, Stefan, Tsang-A-Sjoe, Michel, Raterman, Hennie, Ramwadhdoebe, Tamara, Vugts, Daniëlle, van Dongen, Guus, Huisman, Marc, Hoekstra, Otto, Tak, Paul-Peter, Voskuyl, Alexandre, and van der Laken, Conny
- Published
- 2016
- Full Text
- View/download PDF
6. Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis
- Author
-
Teruel, María, Simeón, Carmen P., Broen, Jasper C., Vonk, Madelon C., Carreira, P., Camps, M. T., García-Portales, Rosa, Delgado-Frías, Esmeralda, Gallego, María, Espinosa, Gerard, Spanish Scleroderma Group, Beretta, L., Airó, Paolo, Lunardi, C., Riemekasten, G., Witte, Torsten, Krieg, Thomas, Kreuter, A., Distler, J. H., Hunzelmann, Nicolas, Koeleman, B. P., Voskuyl, Alexandre E., Schuerwegh, A. J., González-Gay, M. A., Radstake, T. R., Martín, J., Teruel, María, Simeón, Carmen P., Broen, Jasper C., Vonk, Madelon C., Carreira, P., Camps, M. T., García-Portales, Rosa, Delgado-Frías, Esmeralda, Gallego, María, Espinosa, Gerard, Spanish Scleroderma Group, Beretta, L., Airó, Paolo, Lunardi, C., Riemekasten, G., Witte, Torsten, Krieg, Thomas, Kreuter, A., Distler, J. H., Hunzelmann, Nicolas, Koeleman, B. P., Voskuyl, Alexandre E., Schuerwegh, A. J., González-Gay, M. A., Radstake, T. R., and Martín, J.
- Abstract
Introduction The aim of the present study was to investigate the possible role of CD40 and CD40 ligand (CD40LG) genes in the susceptibility and phenotype expression of systemic sclerosis (SSc). Methods In total, 2,670 SSc patients and 3,245 healthy individuals from four European populations (Spain, Germany, The Netherlands, and Italy) were included in the study. Five single-nucleotide polymorphisms (SNPs) of CD40 (rs1883832, rs4810485, rs1535045) and CD40LG (rs3092952, rs3092920) were genotyped by using a predesigned TaqMan allele-discrimination assay technology. Meta-analysis was assessed to determine whether an association exists between the genetic variants and SSc or its main clinical subtypes. Results No evidence of association between CD40 and CD40LG genes variants and susceptibility to SSc was observed. Similarly, no significant statistical differences were observed when SSc patients were stratified by the clinical subtypes, the serologic features, and pulmonary fibrosis. Conclusions Our results do not suggest an important role of CD40 and CD40LG gene polymorphisms in the susceptibility to or clinical expression of SSc.
- Published
- 2012
7. A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with Systemic Sclerosis in a large European cohort
- Author
-
Bossini-Castillo, L., Broen, Jasper C., Simeón, Carmen P., Vonk, Madelon C., Ortego-Centeno, N., González-Escribano, María Francisca, García-Hernández, Francisco José, González-Gay, M. A., Riemekasten, G., Voskuyl, Alexandre E., Schuerwegh, A. J., Airó, Paolo, Laar, Jacob M. van, Hunzelmann, Nicolas, Herrick, A., Radstake, T. R., Martín, J., Rueda, B., Bossini-Castillo, L., Broen, Jasper C., Simeón, Carmen P., Vonk, Madelon C., Ortego-Centeno, N., González-Escribano, María Francisca, García-Hernández, Francisco José, González-Gay, M. A., Riemekasten, G., Voskuyl, Alexandre E., Schuerwegh, A. J., Airó, Paolo, Laar, Jacob M. van, Hunzelmann, Nicolas, Herrick, A., Radstake, T. R., Martín, J., and Rueda, B.
- Published
- 2010
8. Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases.
- Author
-
de Jong, Tamarah D., Vosslamber, Saskia, Mantel, Elise, de Ridder, Sander, Wesseling, John G., van der Pouw Kraan, Tineke C. T. M., Leurs, Cyra, Hegen, Harald, Deisenhammer, Florian, Killestein, Joep, Lundberg, Ingrid E., Vencovsky, Jiri, Nurmohamed, Mike T., van Schaardenburg, Dirkjan, Bultink, Irene E. M., Voskuyl, Alexandre E., Pegtel, D. Michiel, van der Laken, Conny J., Bijlsma, Johannes W. J., and Verweij, Cornelis L.
- Published
- 2016
- Full Text
- View/download PDF
9. Subclinical synovitis detected by macrophage PET, but not MRI, is related to short-term flare of clinical disease activity in early RA patients: an exploratory study.
- Author
-
Gent, Yoony Y. J., ter Wee, Marieke M., Voskuyl, Alexandre E., den Uyl, Debby, Ahmadi, Nazanin, Dowling, Cristina, van Kuijk, Cornelis, Hoekstra, Otto S., Boers, Maarten, Lems, Willem F., and van der Laken, Conny J.
- Published
- 2015
- Full Text
- View/download PDF
10. Productivity at work and quality of life in patients with rheumatoid arthritis.
- Author
-
van Vilsteren, Myrthe, Boot, Cecile RL, Knol, Dirk L, van Schaardenburg, Dirkjan, Voskuyl, Alexandre E, Steenbeek, Romy, and Anema, Johannes R
- Abstract
Background: The aim of this study was to determine which combination of personal, disease-related and environmental factors is best associated with at-work productivity loss in patients with rheumatoid arthritis (RA), and to determine whether at-work productivity loss is associated with the quality of life for these patients. Methods: This study is based on cross-sectional data. Patients completed a questionnaire with personal, disease-related and environmental factors (related to the work environment), and clinical characteristics were obtained from patient medical records. At-work productivity loss was measured with the Work Limitations Questionnaire, and quality of life with the RAND 36. Using linear regression analyses, a multivariate model was built containing the combination of factors best associated with at-work productivity loss. This model was cross-validated internally. We furthermore determined whether at-work productivity loss was associated with quality of life using linear regression analyses. Results: We found that at-work productivity loss was associated with workers who had poorer mental health, more physical role limitations, were ever treated with a biological therapeutic medication, were not satisfied with their work, and had more work instability (R
2 = 0.50 and R2 following cross-validation was 0.32). We found that at-work productivity loss was negatively associated with health-related quality of life, especially with dimensions of mental health, physical role limitations, and pain. Conclusions: We found that at-work productivity loss was associated with personal, work-related, and clinical factors. Although our study results should be interpreted with caution, they provide insight into patients with RA who are at risk for at-work productivity loss. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
11. Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab.
- Author
-
De Jong, Tamarah D., Vosslamber, Saskia, Blits, Marjolein, Wolbink, Gertjan, Nurmohamed, Mike T., van Der Laken, Conny J., Jansen, Gerrit, Voskuyl, Alexandre E., and Verweij, Cornelis L.
- Published
- 2015
- Full Text
- View/download PDF
12. A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility.
- Author
-
López-Isac, Elena, Bossini-Castillo, Lara, Simeon, Carmen P., Egurbide, María Victoria, Alegre-Sancho, Juan José, Callejas, Jose Luis, Roman-Ivorra, José Andrés, Freire, Mayka, Beretta, Lorenzo, Santaniello, Alessandro, Airó, Paolo, Lunardi, Claudio, Hunzelmann, Nicolas, Riemekasten, Gabriela, Witte, Torsten, Kreuter, Alexander, Distler, Jörg H. W., Schuerwegh, Annemie J., Vonk, Madelon C., and Voskuyl, Alexandre E.
- Published
- 2014
- Full Text
- View/download PDF
13. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients.
- Author
-
Raterman, Hennie G., Vosslamber, Saskia, de Ridder, Sander, Nurmohamed, Michael T., Lems, Willem F., Boers, Maarten, van de Wiel, Mark, Dijkmans, Ben A. C., Verweij, Cornelis L., and Voskuyl, Alexandre E.
- Published
- 2012
- Full Text
- View/download PDF
14. An intervention program with the aim to improve and maintain work productivity for workers with rheumatoid arthritis: design of a randomized controlled trial and cost-effectiveness study.
- Author
-
van Vilsteren, Myrthe, Boot, C‚cile R. L., Steenbeek, Romy, van Schaardenburg, Dirkjan, Voskuyl, Alexandre E., and Anema, Johannes R.
- Subjects
RHEUMATOID arthritis ,AUTOIMMUNE diseases ,RANDOMIZED controlled trials ,MEDICAL care ,PATIENTS - Abstract
Background: Workers with rheumatoid arthritis (RA) often experience restrictions in functioning at work and participation in employment. Strategies to maintain work productivity exist, but these interventions do not involve the actual workplace. Therefore the aim of this study is to investigate the (cost)effectiveness of an intervention program at the workplace on work productivity for workers with RA. Methods/design: This study is a randomized controlled trial (RCT) in specialized rheumatology treatment centers in or near Amsterdam, the Netherlands. Randomisation to either the control or the intervention group is performed at patient level. Both groups will receive care as usual by the rheumatologist, and patients in the intervention group will also take part in the intervention program. The intervention program consists of two components; integrated care, including a participatory workplace intervention. Integrated care involves a clinical occupational physician, who will act as care manager, to coordinate the care. The care manager has an intermediate role between clinical and occupational care. The participatory workplace intervention will be guided by an occupational therapist, and involves problem solving by the patient and the patients' supervisor. The aim of the workplace intervention is to achieve consensus between patient and supervisor concerning feasible solutions for the obstacles for functioning at work. Data collection will take place at baseline and after 6 and 12 months by means of a questionnaire. The primary outcome measure is work productivity, measured by hours lost from work due to presenteeism. Secondary outcome measures include sick leave, quality of life, pain and fatigue. Cost-effectiveness of the intervention program will be evaluated from the societal perspective. Discussion: Usual care of primary and outpatient health services is not aimed at improving work productivity. Therefore it is desirable to develop interventions aimed at improving functioning at work. If the intervention program will be (cost)effective, substantial improvements in work productivity might be obtained among workers with RA at lower costs. Results are expected in 2015. Trial registration number: NTR2886 [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
15. Increased incidence of pregnancy complications in women who later develop scleroderma: a case control study.
- Author
-
van Wyk, Linda, van der Marel, Jacolien, Schuerwegh, Annemie J. M., Schouffoer, Anne A., Voskuyl, Alexandre E., Huizinga, Tom W. J., Bianchi, Diana W., and Scherjon, Sicco A.
- Published
- 2011
- Full Text
- View/download PDF
16. Membrane diffusion- and capillary blood volume measurements are not useful as screening tools for pulmonary arterial hypertension in systemic sclerosis: a case control study.
- Author
-
Overbeek, Maria J., Groepenhoff, Herman, Voskuyl, Alexandre E., Smit, Egbert F., Peeters, Jochem W. L., Vonk-Noordegraaf, Anton, Spreeuwenberg, Marieke D., Dijkmans, Ben C., and Boonstra, Anco
- Subjects
HYPERTENSION ,MEDICAL screening ,SYSTEMIC scleroderma ,BIOLOGICAL membranes - Abstract
Background: There is no optimal screening tool for the assessment of pulmonary arterial hypertension (PAH) in patients with systemic sclerosis (SSc). A decreasing transfer factor of the lung for CO (TLCO) is associated with the development of PAH in SSc. TLCO can be partitioned into the diffusion of the alveolar capillary membrane (Dm) and the capillary blood volume (Vc). The use of the partitioned diffusion to detect PAH in SSc is not well established yet. This study evaluates whether Dm and Vc could be candidates for further study of the use for screening for PAH in SSc. Methods: Eleven SSc patients with PAH (SScPAH+), 13 SSc patients without PAH (SScPAH-) and 10 healthy control subjects were included. Pulmonary function testing took place at diagnosis of PAH. TLCO was partitioned according to Roughton and Forster. As pulmonary fibrosis in SSc influences values of the (partitioned) TLCO, these were adjusted for fibrosis score as assessed on HRCT. Results: TLCO as percentage of predicted (%) was lower in SScPAH+ than in SScPAH- (41 ± 7% vs. 63 ± 12%, p < 0.0001, respectively). Dm% in SScPAH+ was decreased as compared with SScPAH- (22 ± 6% vs. 39 ± 12%, p < 0.0001, respectively), also after adjustment for total fibrosis score (before adjustment: B = 17.5, 95% CI 9.0-25.9, p = < 0.0001; after adjustment: B = 14.3, 95% CI 6.0-21.7, p = 0.008). No difference was found in Vc%. There were no correlations between pulmonary hemodynamic parameters and Dm% in the PAH groups. Conclusion: SScPAH+ patients have lower Dm% than SScPAH- patients. There are no correlations between Dm% and hemodynamic parameters of PAH in SScPAH+. These findings do not support further study of the role of partitioning TLCO in the diagnostic work- up for PAH in SSc. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
17. Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis.
- Author
-
Teruel M, Simeon CP, Broen J, Vonk MC, Carreira P, Camps MT, García-Portales R, Delgado-Frías E, Gallego M, Espinosa G, Beretta L, Airó P, Lunardi C, Riemekasten G, Witte T, Krieg T, Kreuter A, Distler JH, Hunzelmann N, Koeleman BP, Voskuyl AE, Schuerwegh AJ, González-Gay MA, Radstake TR, and Martin J
- Subjects
- Genotype, Humans, CD40 Antigens genetics, CD40 Ligand genetics, Genetic Predisposition to Disease genetics, Polymorphism, Single Nucleotide, Scleroderma, Systemic genetics
- Abstract
Introduction: The aim of the present study was to investigate the possible role of CD40 and CD40 ligand (CD40LG) genes in the susceptibility and phenotype expression of systemic sclerosis (SSc)., Methods: In total, 2,670 SSc patients and 3,245 healthy individuals from four European populations (Spain, Germany, The Netherlands, and Italy) were included in the study. Five single-nucleotide polymorphisms (SNPs) of CD40 (rs1883832, rs4810485, rs1535045) and CD40LG (rs3092952, rs3092920) were genotyped by using a predesigned TaqMan allele-discrimination assay technology. Meta-analysis was assessed to determine whether an association exists between the genetic variants and SSc or its main clinical subtypes., Results: No evidence of association between CD40 and CD40LG genes variants and susceptibility to SSc was observed. Similarly, no significant statistical differences were observed when SSc patients were stratified by the clinical subtypes, the serologic features, and pulmonary fibrosis., Conclusions: Our results do not suggest an important role of CD40 and CD40LG gene polymorphisms in the susceptibility to or clinical expression of SSc.
- Published
- 2012
- Full Text
- View/download PDF
18. Bone formation rather than inflammation reflects ankylosing spondylitis activity on PET-CT: a pilot study.
- Author
-
Bruijnen ST, van der Weijden MA, Klein JP, Hoekstra OS, Boellaard R, van Denderen JC, Dijkmans BA, Voskuyl AE, van der Horst-Bruinsma IE, and van der Laken CJ
- Subjects
- Adult, Carbon Radioisotopes, Female, Fluorodeoxyglucose F18, Humans, Inflammation diagnostic imaging, Male, Middle Aged, Pilot Projects, Spondylitis, Ankylosing pathology, Young Adult, Osteogenesis physiology, Positron-Emission Tomography methods, Spondylitis, Ankylosing diagnostic imaging, Tomography, X-Ray Computed methods
- Abstract
Introduction: Positron Emission Tomography - Computer Tomography (PET-CT) is an interesting imaging technique to visualize Ankylosing Spondylitis (AS) activity using specific PET tracers. Previous studies have shown that the PET tracers [18F]FDG and [11C](R)PK11195 can target inflammation (synovitis) in rheumatoid arthritis (RA) and may therefore be useful in AS. Another interesting tracer for AS is [18F]Fluoride, which targets bone formation. In a pilot setting, the potential of PET-CT in imaging AS activity was tested using different tracers, with Magnetic Resonance Imaging (MRI) and conventional radiographs as reference., Methods: In a stepwise approach different PET tracers were investigated. First, whole body [18F]FDG and [11C](R)PK11195 PET-CT scans were obtained of ten AS patients fulfilling the modified New York criteria. According to the BASDAI five of these patients had low and five had high disease activity. Secondly, an extra PET-CT scan using [18F]Fluoride was made of two additional AS patients with high disease activity. MRI scans of the total spine and sacroiliac joints were performed, and conventional radiographs of the total spine and sacroiliac joints were available for all patients. Scans and radiographs were visually scored by two observers blinded for clinical data., Results: No increased [18F]FDG and [11C](R)PK11195 uptake was noticed on PET-CT scans of the first 10 patients. In contrast, MRI demonstrated a total of five bone edema lesions in three out of 10 patients. In the two additional AS patients scanned with [18F]Fluoride PET-CT, [18F]Fluoride depicted 17 regions with increased uptake in both vertebral column and sacroiliac joints. In contrast, [18F]FDG depicted only three lesions, with an uptake of five times lower compared to [18F]Fluoride, and again no [11C](R)PK11195 positive lesions were found. In these two patients, MRI detected nine lesions and six out of nine matched with the anatomical position of [18F]Fluoride uptake. Conventional radiographs showed structural bony changes in 11 out of 17 [18F]Fluoride PET positive lesions., Conclusions: Our PET-CT data suggest that AS activity is reflected by bone activity (formation) rather than inflammation. The results also show the potential value of PET-CT for imaging AS activity using the bone tracer [18F]Fluoride. In contrast to active RA, inflammation tracers [18F]FDG and [11C](R)PK11195 appeared to be less useful for AS imaging.
- Published
- 2012
- Full Text
- View/download PDF
19. Platelet-derived growth factor receptor-β and epidermal growth factor receptor in pulmonary vasculature of systemic sclerosis-associated pulmonary arterial hypertension versus idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: a case-control study.
- Author
-
Overbeek MJ, Boonstra A, Voskuyl AE, Vonk MC, Vonk-Noordegraaf A, van Berkel MP, Mooi WJ, Dijkmans BA, Hondema LS, Smit EF, and Grünberg K
- Subjects
- Adult, Aged, Biomarkers metabolism, Case-Control Studies, ErbB Receptors analysis, Familial Primary Pulmonary Hypertension, Female, Humans, Hypertension, Pulmonary etiology, Hypertension, Pulmonary physiopathology, Immunohistochemistry, Lung blood supply, Lung metabolism, Male, Middle Aged, Pulmonary Artery metabolism, Pulmonary Artery physiopathology, Pulmonary Veins metabolism, Pulmonary Veins physiopathology, Pulmonary Veno-Occlusive Disease metabolism, Pulmonary Veno-Occlusive Disease physiopathology, Receptor, Platelet-Derived Growth Factor beta analysis, Scleroderma, Systemic complications, Scleroderma, Systemic physiopathology, Biomarkers analysis, ErbB Receptors biosynthesis, Hypertension, Pulmonary metabolism, Receptor, Platelet-Derived Growth Factor beta biosynthesis, Scleroderma, Systemic metabolism
- Abstract
Introduction: Systemic sclerosis (SSc) complicated by pulmonary arterial hypertension (PAH) carries a poor prognosis, despite pulmonary vascular dilating therapy. Platelet-derived growth factor receptor-β (PDGFR-β) and epidermal growth factor receptor (EGFR) are potential therapeutic targets for PAH because of their proliferative effects on vessel remodelling. To explore their role in SScPAH, we compared PDGFR- and EGFR-mmunoreactivity in lung tissue specimens from SScPAH. We compared staining patterns with idiopathic PAH (IPAH) and pulmonary veno-occlusive disease (PVOD), as SScPAH vasculopathy differs from IPAH and sometimes displays features of PVOD. Immunoreactivity patterns of phosphorylated PDGFR-β (pPDGFR-β) and the ligand PDGF-B were evaluated to provide more insight into the patterns of PDGFR-b activation., Methods: Lung tissue specimens from five SScPAH, nine IPAH, six PVOD patients and five controls were examined. Immunoreactivity was scored for presence, distribution and intensity., Results: All SScPAH and three of nine IPAH cases (P = 0.03) showed PDGFR-β-immunoreactivity in small vessels (arterioles/venules); of five SScPAH vs. two of nine IPAH cases (P = 0.02) showed venous immunoreactivity. In small vessels, intensity was stronger in SScPAH vs. IPAH. No differences were found between SScPAH and PVOD. One of five normal controls demonstrated focally mild immunoreactivity. There were no differences in PDGF-ligand and pPDGFR-b-immunoreactivity between patient groups; however, pPDGFR-b-immunoreactivity tended to be more prevalent in SScPAH small vasculature compared to IPAH. Vascular EGFR-immunoreactivity was limited to arterial and arteriolar walls, without differences between groups. No immunoreactivity was observed in vasculature of normals., Conclusions: PDGFR-β-immunoreactivity in SScPAH is more common and intense in small- and post-capillary vessels than in IPAH and does not differ from PVOD, fitting in with histomorphological distribution of vasculopathy. PDGFR-β immunoreactivity pattern is not paralleled by pPDGFR-β or PDGF-B patterns. PDGFR-β- and EGFR-immunoreactivity of pulmonary vessels distinguishes PAH patients from controls.
- Published
- 2011
- Full Text
- View/download PDF
20. Use of methotrexate therapy is not associated with decreased prevalence of metabolic syndrome.
- Author
-
Raterman HG, Voskuyl AE, Dijkmans BA, and Nurmohamed MT
- Subjects
- Arthritis, Rheumatoid complications, Arthritis, Rheumatoid drug therapy, Humans, Metabolic Syndrome complications, Prevalence, Antirheumatic Agents therapeutic use, Metabolic Syndrome epidemiology, Methotrexate therapeutic use
- Published
- 2009
- Full Text
- View/download PDF
21. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
- Author
-
van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, and Voskuyl AE
- Subjects
- Aged, Case-Control Studies, Female, Follow-Up Studies, Humans, Hydroxychloroquine administration & dosage, Male, Methotrexate administration & dosage, Middle Aged, Odds Ratio, Regression Analysis, Risk Factors, Antirheumatic Agents administration & dosage, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid epidemiology, Cardiovascular Diseases epidemiology, Sulfasalazine administration & dosage
- Abstract
Rheumatoid arthritis (RA) is characterized by inflammation and an increased risk for cardiovascular disease (CVD). This study investigates possible associations between CVD and the use of conventional disease-modifying antirheumatic drugs (DMARDs) in RA. Using a case control design, 613 RA patients (5,649 patient-years) were studied, 72 with CVD and 541 without CVD. Data on RA, CVD and drug treatment were evaluated from time of RA diagnosis up to the first cardiovascular event or the end of the follow-up period. The dataset was categorized according to DMARD use: sulfasalazine (SSZ), hydroxychloroquine (HCQ) or methotrexate (MTX). Odds ratios (ORs) for CVD, corrected for age, gender, smoking and RA duration, were calculated per DMARD group. Patients who never used SSZ, HCQ or MTX were used as a reference group. MTX treatment was associated with a significant CVD risk reduction, with ORs (95% CI): 'MTX only', 0.16 (0.04 to 0.66); 'MTX and SSZ ever', 0.20 (0.08 to 0.51); and 'MTX, SSZ and HCQ ever', 0.20 (0.08 to 0.54). The risk reductions remained significant after additional correction for the presence of rheumatoid factor and erosions. After correction for hypertension, diabetes and hypercholesterolemia, 'MTX or SSZ ever' and 'MTX, SSZ and HCQ ever' showed significant CVD risk reduction. Rheumatoid factor positivity and erosions both increased CVD risk, with ORs of 2.04 (1.02 to 4.07) and 2.36 (0.92 to 6.08), respectively. MTX and, to a lesser extent, SSZ were associated with significantly lower CVD risk compared to RA patients who never used SSZ, HCQ or MTX. We hypothesize that DMARD use, in particular MTX use, results in powerful suppression of inflammation, thereby reducing the development of atherosclerosis and subsequently clinically overt CVD.
- Published
- 2006
- Full Text
- View/download PDF
22. Deficiency of functional mannose-binding lectin is not associated with infections in patients with systemic lupus erythematosus.
- Author
-
Bultink IE, Hamann D, Seelen MA, Hart MH, Dijkmans BA, Daha MR, and Voskuyl AE
- Subjects
- Adult, Bacterial Infections etiology, Complement C4 metabolism, Female, Humans, Lupus Erythematosus, Systemic blood, Male, Bacterial Infections epidemiology, Lupus Erythematosus, Systemic immunology, Lupus Erythematosus, Systemic microbiology, Mannose-Binding Lectin blood, Mannose-Binding Lectin deficiency
- Abstract
Infection imposes a serious burden on patients with systemic lupus erythematosus (SLE). The increased infection rate in SLE patients has been attributed in part to defects of immune defence. Recently, the lectin pathway of complement activation has also been suggested to play a role in the occurrence of infections in SLE. In previous studies, SLE patients homozygous for mannose-binding lectin (MBL) variant alleles were at an increased risk of acquiring serious infections in comparison with patients who were heterozygous or homozygous for the normal allele. This association suggests a correlation between functional MBL level and occurrence of infections in SLE patients. We therefore investigated the biological activity of MBL and its relationship with the occurrence of infections in patients with SLE. Demographic and clinical data were collected in 103 patients with SLE. Functional MBL serum levels and MBL-induced C4 deposition were measured by enzyme-linked immunosorbent assay using mannan as coat and an MBL- or C4b-specific monoclonal antibody. The complete MBL-dependent pathway activity was determined by using an assay that measures the complete MBL pathway activity in serum, starting with binding of MBL to mannan, and was detected with a specific monoclonal antibody against C5b-9. Charts were systematically reviewed to obtain information on documented infections since diagnosis of SLE. Major infections were defined as infections requiring hospital admission and intravenous administration of antibiotics. In total, 115 infections since diagnosis of lupus, including 42 major infections, were documented in the 103 SLE patients (mean age 41 +/- 13 years, mean disease duration 7 +/- 4 years). The percentage of SLE patients with severe MBL deficiency was similar to that in 100 healthy controls: 13% versus 14%, respectively. Although deposition of C4 to mannan and MBL pathway activity were reduced in 21% and 43% of 103 SLE patients, respectively, neither functional MBL serum levels nor MBL pathway activity was associated with infections or major infections in regression analyses. In conclusion, SLE patients frequently suffer from infections, but deficiency of functional MBL does not confer additional risk.
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.